The Health Sciences Institute is intended to provide cutting-edge health information.
Nothing on this site should be interpreted as personal medical advice. Always consult with your doctor before changing anything related to your healthcare.

Another new cholesterol-lowering med may be riskiest yet

Of all the crazy tricks Big Pharma has tried to pull for the purpose of lowering our cholesterol, this is the boldest — and most dangerous — stunt yet.

I thought I had seen everything, but then Inclisiran came along.

And you need to know about it now, before it even hits the market.

Because should your doctor ever try to pull this one off on you, don’t just walk, but run as fast as you can in the other direction.

The ‘cure’ that can kill

Just last month I warned you about another deadly cholesterol-lowering scam.

It involves a cholesterol-lowering med called Repatha combined with a statin pill. As I said, the headlines I saw when that dangerous duo was announced made it sound like a cure for heart disease had been found.

Of course, nothing could be farther from the truth.

But now, along comes Inclisiran. And this is even worse, if that’s possible.

Like Repatha, Inclisiran is a PCSK9 inhibitor, a new kind of cholesterol med that’s like a statin on steroids. PCSK9 drugs are injected into you and interfere with a key gene that regulates cholesterol in your body.

And get this – the whole idea of these PCSK9 drugs was to mimic people who have super-low cholesterol numbers. Those people actually aren’t healthy and the only reason their cholesterol numbers are that low naturally is because they have a rare genetic disease!

As I told you, these new drugs are not only expensive, but time-consuming. Repatha users have to get a shot every two weeks or hook themselves up to an on-body infuser once a month.

So, now the mad scientists in pharma land have gone one step further, and created the “next-level” PCSK9 inhibitor that will only need to be injected twice a year. Inclisiran (I have no idea how it’s pronounced, either) is said to be able to force cholesterol numbers down to unheard of levels for months at a time.

In other words, this is brand new territory.

But what we already know about bargain-basement cholesterol numbers isn’t good. Driving numbers that low can be a prescription for problems that include trouble thinking and reasoning. It’s even been linked to dementia and Alzheimer’s disease.

Your body needs a certain amount of cholesterol to stay healthy, to make vitamin D and have proper hormone production.

But it looks like caution and common sense have been thrown to the wind, because what will happen when the FDA gives Inclisiran the green rubber stamp and sends it out the door is anyone’s guess.

Already we know, based on the clinical trial of 500 patients (or human guinea pigs), that the “most common” side effects from Inclisiran are muscle pain, swelling of nasal passages, headache, back pain and diarrhea.

One of the patients in the trial died, but he’s been swept under the carpet by the study’s lead author, Professor Kausik Ray, as being someone who had heart disease and “died suddenly in a restaurant.”

Seriously? Isn’t this drug for people with heart disease?

Can you imagine if they were conducting a test of a dietary supplement and one of the participants suddenly keeled over while eating? Why, all the alarm bells would be blaring as loud as possible.

But Professor Ray is a busy man. He’s currently involved in seven other trials as well as having received research grants from the likes of Pfizer, Amgen, and Sanofi. I guess he can’t be bothered with worrying about one little death in his cholesterol drug study.

Look, everything we now know about these new meds and the danger of rock-bottom cholesterol numbers should be enough warning all on its own to stay far, far away from these PCSK9 inhibitor drugs.

And that’s especially true of this newest one.

“Twice-a-year shot for cholesterol holds promise” Dennis Thompson, November 6, 2016, CBD News,